Drug Type Synthetic peptide |
Synonyms 84AAAPI 14AA, Nerofe |
Target |
Action inhibitors, stimulants |
Mechanism IL-33R inhibitors(Interleukin-1 receptor-like 1 inhibitors), Angiogenesis inhibitors, Apoptosis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | Israel | 25 Oct 2018 | |
Myelodysplastic Syndromes | Phase 2 | Israel | 25 Oct 2018 | |
Ovarian Cancer | Phase 2 | Israel | 06 Sep 2018 | |
Triple Negative Breast Cancer | Phase 2 | Israel | 06 Sep 2018 | |
KRAS G12C mutation Solid Tumors | Phase 1 | United States | 12 Apr 2023 | |
KRAS mutation-related tumors | Phase 1 | United States | 12 Apr 2023 | |
Alzheimer Disease | Phase 1 | United States | 10 Aug 2022 | |
Solid tumor | Phase 1 | United States | 10 Aug 2022 | |
Recurrent Myelodysplastic Syndrome | Phase 1 | United States | 18 Jun 2020 | |
Advanced cancer | Phase 1 | Israel | 01 Dec 2013 |